Longest survival follow-up ever reported for immunotherapy treatment in this setting
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Express Scripts to add Zepbound to National Preferred Formulary
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Subscribe To Our Newsletter & Stay Updated
